Hematocrit

Percent of blood volume that is red blood cells - the key marker to monitor on TRT and GH protocols.

What Hematocrit Measures

Hematocrit measures the proportion of blood volume occupied by red blood cells. Elevated hematocrit thickens blood, increasing cardiovascular risk (stroke, deep vein thrombosis, pulmonary embolism).

The single most reliable lab abnormality on TRT is rising hematocrit - testosterone stimulates erythropoiesis. Most TRT users see hematocrit rise 2–6 percentage points over 12 months. Sustained values >52% in men typically warrant intervention: dose reduction, blood donation, or cycling off briefly.

What Affects This Biomarker

Hematocrit is influenced by: testosterone (the primary driver in optimization users), GH protocols (modest rise), erythropoietin / EPO, altitude (high altitude raises), dehydration (transient elevation - always rehydrate before draw), smoking (chronic elevation), sleep apnea (chronic elevation), and pharmacologic agents - TRT raises significantly; GH raises modestly; SGLT2 inhibitors raise modestly; ARA-290 doesn't affect it (a key advantage).

In the Context of Peptide Protocols

For TRT users: baseline + every 3 months for first year, then biannual. >52% sustained = action: dose reduction, twice-weekly injection (smoother levels), more frequent blood donation, or short cycle off. For GH protocol users: monitor at 6 weeks and quarterly - typically rises 1–3 points; concerning above 52%. Always rehydrate before draw.

Peptides That Commonly Move Hematocrit

Upload any lab PDF and MyProtocolStack maps your values to Hematocrit and 40+ other biomarkers. StackAI interprets the trend in context of your protocol.